I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

CMSC 2024 | May 29, 2024 - Jun 1, 2024

Neurology

Using cutting-edge technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other chronic, debilitating neurological disorders. Our goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.

Available rooms
1 of 1

  • Frexalimab in MS

  • Multiple Sclerosis

    Multiple sclerosis (MS) is an autoimmune disorder that causes neuroinflammation in the brain and spinal cord. The resulting lesions can either shrink or remain "chronically active" over the course of years, leading to accelerated loss of brain volume. This leads to unpredictable symptoms, such as vision problems, challenges with cognition, and difficulty with physical activity.